Disclosure statement Supported by the National Institutes of Health (grants R01 HL163618, R61 HL158941, and R21 HL172038 [to E.L.B.] and grant U01 AI155299 [to K.N.C. and J.C.H.]. The funding sources were not involved in any component of the study design, analysis, or article preparation. Disclosure of potential conflict of interest: K. N. Cahill has served on scientific advisory boards for AstraZeneca, Sanofi, Genentech, Regeneron, Novartis, GSK, and Eli Lilly; has served as a consultant for Ribon Therapeutics, Third Harmonic Bio, Ramble Health, and Verantos; reports royalties from UpToDate; and reports research support from Novo Nordisk. E. L. Brittain has received investigator-initiated grant funding outside the scope of this work. B. M. Kahwash has served on scientific advisory boards for Sanofi and GSK, reports research support from GlaxoSmithKline, reports speakers’ bureau participation for AstraZeneca, and has equity in Doximity. The rest of the authors declare that they have no relevant conflicts of interest.